Free Trial
NASDAQ:VIGL

Vigil Neuroscience Q4 2023 Earnings Report

Vigil Neuroscience logo
$2.75 +0.19 (+7.42%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$2.70 -0.04 (-1.64%)
As of 05/2/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vigil Neuroscience EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.56
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Vigil Neuroscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vigil Neuroscience Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, March 26, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Vigil Neuroscience's Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Vigil Neuroscience Earnings Headlines

🥾⛏️👷‍♂️ What I Learned From Numerous Mine Visits...
Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining stocks like most gold analyst CFAs, I decided to visit every significant gold mine I could. 10+ site visits later, I've confirmed my theory... That the most profitable mines share three specific characteristics. When you find all three together, the returns can be staggering.
William Blair Remains a Buy on Vigil Neuroscience Inc (VIGL)
See More Vigil Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vigil Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vigil Neuroscience and other key companies, straight to your email.

About Vigil Neuroscience

Vigil Neuroscience (NASDAQ:VIGL), a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

View Vigil Neuroscience Profile

More Earnings Resources from MarketBeat